+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.

      Journal of clinical neuromuscular disease
      Adolescent, Adult, Aged, Aged, 80 and over, Autoimmune Diseases of the Nervous System, drug therapy, Dose-Response Relationship, Drug, Exanthema, chemically induced, Female, Headache, Home Care Services, statistics & numerical data, trends, Humans, Immunoglobulins, Intravenous, administration & dosage, adverse effects, Male, Middle Aged, Monitoring, Physiologic, Outcome Assessment (Health Care), Retrospective Studies, Treatment Outcome, Young Adult

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          To examine the overall safety of intravenous immunoglobulin (IVIG) administered according to a clinically defined, home-based therapeutic regimen in patients with neuroimmunologic diseases. A total of 1,085 infusions of a new liquid IVIG 10% preparation were administered to 70 patients diagnosed with neuroimmunologic diseases over a 9-month period. These infusions were retrospectively reviewed for safety and tolerability. A very favorable adverse effect (AE) rate (4.7%) was calculated over a wide range of doses (0.9-2.14 g/kg). There were no serious AEs reported, even among patients naive to IVIG therapy. Of 51 nonserious AEs, 53% occurred in 5 patients. The results of this review of 1,085 high-dose liquid IVIG infusions using a closely monitored, yet highly flexible, home-based therapeutic regimen indicate a very favorable tolerability profile in patients with neuroimmunologic disorders, even in those who were new to IVIG therapy.

          Related collections

          Author and article information


          Comment on this article